Mandar A Aras, MD
Cardiovascular Disease (Cardiology) · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
- Since medical school
- 15 years
- University of Pittsburgh School of Medicine, 2011
Offices
2 locations · University of California San Francisco · Regents of the University of California
Hospitals listed: Marinhealth Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Aras’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A130155 · Current
Licensed to practise in California · since 2014 · expires 2027-10-31 · University of Pittsburgh School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Advanced Heart Failure and Transplant
- American Board of Internal Medicine - Cardiovascular Disease
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$82,619
Medicare paid this office $82,619 for 316 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 151 | $24,138 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $18,483 | $105 |
| New patient visit (60+ min) | 68 | $10,505 | $154 |
| Biopsy of heart muscle | 14 | $3,220 | $189 |
| Long return visit (40+ min) | 13 | $3,169 | $158 |
See all 9 services
| Long return visit (40+ min) | 151 | $24,138 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $18,483 | $105 |
| New patient visit (60+ min) | 68 | $10,505 | $154 |
| Biopsy of heart muscle | 14 | $3,220 | $189 |
| Long return visit (40+ min) | 13 | $3,169 | $158 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 138 | $2,499 | $15 |
| Test for exercise-induced heart and lung stress | 35 | $2,021 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,997 | $154 |
| Evaluation of lower heart chamber assist device | 16 | $1,671 | $29 |
Who their Medicare patients are
316 Original Medicare patients in 2024. Average age 71 · Under 65 21% · 85 and older 9% · Women 35% · Also on Medicaid 31% · Health risk score 2.98. Sicker patients than 9 in 10 peers; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Heart failure 75% · Chronic kidney disease 56% · Coronary heart disease 54% · Atrial fibrillation 51% · Diabetes 41% · Depression 26% · Cancer 22% · COPD 20% · Stroke 14% · Dementia 5%.
The office billed $569,957, Medicare allowed $107,740 and paid $82,619; for 1,615 services of 42 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 316 | 1,615 | 71 | 2.98 | $569,957 | $82,619 |
| 2023 | 301 | 2,186 | 70 | 2.78 | $459,946 | $74,001 |
| 2022 | 259 | 600 | 69 | 2.92 | $396,085 | $62,916 |
| 2021 | 237 | 631 | 68 | 3.02 | $369,592 | $56,169 |
| 2020 | 238 | 682 | 66 | 2.87 | $399,052 | $56,558 |
| 2019 | 247 | 733 | 65 | 3.06 | $437,186 | $61,532 |
| 2018 | 137 | 346 | 66 | 2.60 | $210,593 | $30,906 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 131 | $22,066 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $19,829 | $107 |
| New patient visit (60+ min) | 75 | $11,483 | $153 |
| Test for exercise-induced heart and lung stress | 58 | $3,557 | $60 |
| Biopsy of heart muscle | 16 | $3,297 | $194 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $236 | $9 |
2022: 7 services
| Long return visit (40+ min) | 126 | $22,518 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $14,278 | $91 |
| New patient visit (60+ min) | 69 | $10,867 | $157 |
| Insertion of tube in right heart chambers for measurement | 18 | $2,022 | $106 |
| Test for exercise-induced heart and lung stress | 20 | $1,169 | $58 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $969 | $88 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $146 | $9 |
2021: 8 services
| Long return visit (40+ min) | 116 | $21,572 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $10,988 | $92 |
| New patient visit (60+ min) | 54 | $8,651 | $160 |
| Evaluation of lower heart chamber assist device | 18 | $4,357 | $34 |
| Insertion of tube in right heart chambers for measurement | 19 | $1,905 | $95 |
| Test for exercise-induced heart and lung stress | 30 | $1,860 | $62 |
| Return visit (30+ min) | 11 | $862 | $62 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 31 | $280 | $9 |
2020: 10 services
| Long return visit (40+ min) | 124 | $17,368 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $12,164 | $93 |
| Evaluation of lower heart chamber assist device | 26 | $6,262 | $44 |
| New patient visit (60+ min) | 42 | $6,118 | $146 |
| Biopsy of heart muscle | 16 | $3,353 | $197 |
| Return visit (30+ min) | 23 | $1,931 | $72 |
| Insertion of tube in right heart chambers for measurement | 16 | $1,676 | $105 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $928 | $71 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $285 | $12 |
| Test to measure exhaled air and carbon dioxide for evaluation of lung function | 24 | $224 | $9 |
2019: 10 services
| Long return visit (40+ min) | 125 | $17,685 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $14,809 | $92 |
| Evaluation of lower heart chamber assist device | 25 | $7,318 | $41 |
| New patient visit (60+ min) | 41 | $5,932 | $145 |
| Critical care, first 30-74 minutes | 15 | $3,480 | $193 |
| Biopsy of heart muscle | 11 | $3,335 | $176 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,327 | $179 |
| Insertion of tube in right heart chambers for measurement | 19 | $2,136 | $107 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $304 | $11 |
| Test to measure exhaled air and carbon dioxide for evaluation of lung function | 25 | $239 | $9 |
2018: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $8,986 | $93 |
| Long return visit (40+ min) | 55 | $7,638 | $97 |
| New patient visit (60+ min) | 25 | $3,610 | $144 |
| Evaluation of lower heart chamber assist device | 12 | $2,312 | $41 |
| Insertion of tube in right heart chambers for measurement | 13 | $1,457 | $112 |
Medicaid work
$36,175 in 2024
Medicaid paid $36,175 for 256 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 208 | $32,623 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 48 | $3,551 |
| 2024 | 256 | 2 | 27 | $36,175 |
| 2023 | 266 | 2 | 25 | $27,971 |
| 2022 | 87 | 1 | 19 | $11,892 |
| 2021 | 102 | 3 | 16 | $9,631 |
| 2020 | 61 | 2 | 18 | $5,050 |
| 2019 | 125 | 2 | 19 | $12,386 |
| 2018 | 29 | 1 | 12 | $2,289 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 134 | $17,793 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 132 | $10,179 |
2022
| Long return visit (40+ min) | 87 | $11,892 |
2021
| Long return visit (40+ min) | 42 | $5,566 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 48 | $3,443 |
| Telehealth originating site facility fee | 12 | $621 |
2020
| Long return visit (40+ min) | 48 | $4,933 |
| Telehealth transmission, per minute, professional services bill separately | 13 | $117 |
2019
| Long return visit (40+ min) | 82 | $8,017 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 43 | $4,369 |
2018
| Long return visit (40+ min) | 29 | $2,289 |
Drugs they prescribed that Part D paid
$8,446,299
Pharmacies billed $8,446,299 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
845 generic and 664 brand-name prescriptions · $8,446,299 in drug cost · 31 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyndamax | 278 | $7,106,775 | $25,564 |
| Vyndaqel | 41 | $984,809 | $24,020 |
| Jardiance | 113 | $113,829 | $1,007 |
| Farxiga | 76 | $60,736 | $799 |
| Eliquis | 45 | $47,181 | $1,048 |
See all 27 drugs
| Vyndamax | 278 | $7,106,775 | $25,564 |
| Vyndaqel | 41 | $984,809 | $24,020 |
| Jardiance | 113 | $113,829 | $1,007 |
| Farxiga | 76 | $60,736 | $799 |
| Eliquis | 45 | $47,181 | $1,048 |
| Entresto | 31 | $28,470 | $918 |
| Wegovy | 15 | $20,666 | $1,378 |
| Xarelto | 14 | $9,767 | $698 |
| Mycophenolate Mofetil | 15 | $3,695 | $246 |
| Tacrolimus | 18 | $3,166 | $176 |
| Incruse Ellipta | 11 | $3,019 | $274 |
| Potassium Chloride | 27 | $1,757 | $65 |
| Bumetanide | 40 | $1,528 | $38 |
| Spironolactone | 116 | $1,192 | $10 |
| Atorvastatin | 56 | $764 | $14 |
| Metoprolol | 52 | $725 | $14 |
| Rosuvastatin | 20 | $660 | $33 |
| Warfarin | 27 | $561 | $21 |
| Ceftriaxone | 22 | $537 | $24 |
| Carvedilol | 33 | $487 | $15 |
| Losartan | 45 | $430 | $10 |
| Hydralazine | 32 | $391 | $12 |
| Ezetimibe | 12 | $357 | $30 |
| Furosemide | 46 | $259 | $6 |
| Amlodipine Besylate | 44 | $154 | $4 |
| Pravastatin | 11 | $132 | $12 |
| Gabapentin | 20 | $90 | $4 |
Year by year
| 2024 | 1,509 | 203 | None | 44% | $8,446,299 |
| 2023 | 1,501 | 204 | None | 27% | $2,969,045 |
| 2022 | 1,145 | 166 | 0% (0) | None | $1,736,790 |
| 2021 | 997 | 127 | 0% (0) | None | $1,782,495 |
| 2020 | 958 | 131 | 0% (0) | 20% | $1,270,060 |
| 2019 | 636 | 115 | 0% (0) | None | $1,528,772 |
| 2018 | 197 | 57 | 0% (0) | None | $251,115 |
| 2014 | 23 | None | 0% (0) | None | $1,675 |
| 2013 | 35 | 17 | None | None | $4,316 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Vyndamax | 78 | $2,063,837 | $26,459 |
| Opsumit | 14 | $180,159 | $12,868 |
| Adcirca | 17 | $69,695 | $4,100 |
| Farxiga | 69 | $65,658 | $952 |
| Jardiance | 45 | $56,588 | $1,258 |
| Entresto | 62 | $50,364 | $812 |
| Eliquis | 51 | $44,230 | $867 |
| Everolimus | 18 | $43,700 | $2,428 |
| Posaconazole | 11 | $32,956 | $2,996 |
| Sildenafil Citrate | 15 | $16,323 | $1,088 |
| Xarelto | 11 | $13,901 | $1,264 |
| Tacrolimus | 39 | $7,885 | $202 |
| Mycophenolate Mofetil | 26 | $5,532 | $213 |
| Potassium Chloride | 24 | $2,340 | $98 |
| Ceftriaxone | 37 | $1,961 | $53 |
| Bumetanide | 47 | $1,390 | $30 |
| Atorvastatin | 73 | $1,312 | $18 |
| Torsemide | 11 | $1,185 | $108 |
| Isosorbide Mononitrate Er | 29 | $1,154 | $40 |
| Rosuvastatin | 25 | $1,148 | $46 |
| Spironolactone | 95 | $1,109 | $12 |
| Metoprolol | 64 | $1,024 | $16 |
| Losartan | 50 | $1,023 | $20 |
| Carvedilol | 40 | $919 | $23 |
| Hydralazine | 39 | $912 | $23 |
| Warfarin | 24 | $889 | $37 |
| Ezetimibe | 14 | $597 | $43 |
| Pravastatin | 16 | $542 | $34 |
| Bisoprolol | 18 | $492 | $27 |
| Eplerenone | 11 | $474 | $43 |
| Digoxin | 19 | $462 | $24 |
| Furosemide | 27 | $401 | $15 |
| Omeprazole | 18 | $368 | $20 |
| Amlodipine Besylate | 28 | $363 | $13 |
| Amiodarone | 11 | $333 | $30 |
| Prednisone | 15 | $129 | $9 |
| Lisinopril | 17 | $86 | $5 |
| Amoxicillin | 11 | $21 | $2 |
2022: 30 drugs
| Uptravi | 30 | $699,988 | $23,333 |
| Opsumit | 24 | $295,601 | $12,317 |
| Letairis | 14 | $154,856 | $11,061 |
| Adcirca | 23 | $96,704 | $4,205 |
| Tadalafil | 33 | $48,986 | $1,484 |
| Entresto | 52 | $46,319 | $891 |
| Farxiga | 42 | $32,104 | $764 |
| Eliquis | 27 | $19,775 | $732 |
| Jardiance | 13 | $12,758 | $981 |
| Tacrolimus | 56 | $10,601 | $189 |
| Potassium Chloride | 29 | $2,235 | $77 |
| Mycophenolate Mofetil | 11 | $1,548 | $141 |
| Bumetanide | 41 | $1,170 | $29 |
| Rosuvastatin | 20 | $917 | $46 |
| Atorvastatin | 77 | $894 | $12 |
| Carvedilol | 58 | $840 | $14 |
| Torsemide | 17 | $839 | $49 |
| Isosorbide Mononitrate Er | 44 | $777 | $18 |
| Warfarin | 14 | $702 | $50 |
| Bisoprolol | 14 | $689 | $49 |
| Spironolactone | 62 | $520 | $8 |
| Digoxin | 21 | $484 | $23 |
| Hydralazine | 25 | $458 | $18 |
| Metoprolol | 31 | $410 | $13 |
| Gabapentin | 12 | $351 | $29 |
| Losartan | 28 | $349 | $12 |
| Furosemide | 36 | $277 | $8 |
| Clonidine | 16 | $214 | $13 |
| Amlodipine Besylate | 18 | $105 | $6 |
| Lisinopril | 11 | $41 | $4 |
2021: 33 drugs
| Uptravi | 30 | $699,188 | $23,306 |
| Vyndamax | 13 | $250,345 | $19,257 |
| Opsumit | 20 | $235,973 | $11,799 |
| Vyndaqel | 12 | $226,188 | $18,849 |
| Entresto | 53 | $50,069 | $945 |
| Ambrisentan | 12 | $46,884 | $3,907 |
| Tadalafil | 21 | $41,271 | $1,965 |
| Everolimus | 13 | $36,415 | $2,801 |
| Eliquis | 14 | $10,519 | $751 |
| Tacrolimus | 31 | $7,896 | $255 |
| Enoxaparin | 13 | $4,254 | $327 |
| Bumetanide | 26 | $2,138 | $82 |
| Mycophenolate Mofetil | 11 | $1,434 | $130 |
| Eplerenone | 20 | $1,403 | $70 |
| Isosorbide Dinitrate | 12 | $1,236 | $103 |
| Bisoprolol | 13 | $1,216 | $94 |
| Potassium Chloride | 21 | $1,037 | $49 |
| Isosorbide Mononitrate Er | 40 | $926 | $23 |
| Torsemide | 18 | $743 | $41 |
| Carvedilol | 42 | $649 | $15 |
| Hydralazine | 38 | $633 | $17 |
| Atorvastatin | 46 | $613 | $13 |
| Warfarin | 12 | $380 | $32 |
| Metoprolol | 25 | $351 | $14 |
| Spironolactone | 40 | $334 | $8 |
| Rosuvastatin | 18 | $314 | $17 |
| Digoxin | 30 | $312 | $10 |
| Omeprazole | 21 | $272 | $13 |
| Losartan | 18 | $244 | $14 |
| Pantoprazole | 18 | $225 | $12 |
| Furosemide | 45 | $177 | $4 |
| Allopurinol | 16 | $70 | $4 |
| Lisinopril | 17 | $68 | $4 |
2020: 33 drugs
| Uptravi | 23 | $451,621 | $19,636 |
| Vyndaqel | 22 | $440,010 | $20,000 |
| Sandostatin Lar Depot | 12 | $52,206 | $4,351 |
| Ambrisentan | 16 | $45,196 | $2,825 |
| Entresto | 27 | $23,888 | $885 |
| Alyq | 20 | $10,214 | $511 |
| Tacrolimus | 28 | $7,077 | $253 |
| Basaglar Kwikpen U-100 | 16 | $5,461 | $341 |
| Enoxaparin | 19 | $4,103 | $216 |
| Potassium Chloride | 33 | $2,680 | $81 |
| Eplerenone | 22 | $2,315 | $105 |
| Bumetanide | 28 | $1,874 | $67 |
| Sildenafil Citrate | 16 | $1,529 | $96 |
| Warfarin | 41 | $1,295 | $32 |
| Isosorbide Mononitrate Er | 45 | $846 | $19 |
| Atorvastatin | 44 | $709 | $16 |
| Metoprolol | 40 | $597 | $15 |
| Bisoprolol | 22 | $560 | $25 |
| Doxycycline Hyclate | 13 | $479 | $37 |
| Torsemide | 33 | $476 | $14 |
| Spironolactone | 38 | $392 | $10 |
| Hydralazine | 18 | $301 | $17 |
| Carvedilol | 22 | $267 | $12 |
| Omeprazole | 11 | $244 | $22 |
| Losartan | 29 | $234 | $8 |
| Lansoprazole | 17 | $205 | $12 |
| Furosemide | 21 | $200 | $10 |
| Gabapentin | 13 | $180 | $14 |
| Digoxin | 12 | $172 | $14 |
| Amlodipine Besylate | 38 | $150 | $4 |
| Lisinopril | 20 | $122 | $6 |
| Sulfamethoxazole-Trimethoprim | 17 | $70 | $4 |
| Fluconazole | 11 | $64 | $6 |
2019: 22 drugs
| Uptravi | 41 | $938,224 | $22,884 |
| Opsumit | 15 | $153,393 | $10,226 |
| Adcirca | 13 | $57,114 | $4,393 |
| Tadalafil | 16 | $37,045 | $2,315 |
| Sildenafil Citrate | 12 | $8,116 | $676 |
| Entresto | 16 | $7,812 | $488 |
| Alyq | 20 | $2,030 | $102 |
| Bumetanide | 19 | $1,960 | $103 |
| Potassium Chloride | 22 | $1,241 | $56 |
| Duloxetine | 11 | $844 | $77 |
| Isosorbide Mononitrate Er | 16 | $739 | $46 |
| Metoprolol | 16 | $658 | $41 |
| Atorvastatin | 35 | $587 | $17 |
| Spironolactone | 44 | $353 | $8 |
| Warfarin | 17 | $346 | $20 |
| Digoxin | 21 | $293 | $14 |
| Pravastatin | 12 | $245 | $20 |
| Carvedilol | 40 | $243 | $6 |
| Losartan | 15 | $157 | $10 |
| Amlodipine Besylate | 24 | $126 | $5 |
| Lisinopril | 11 | $96 | $9 |
| Furosemide | 13 | $89 | $7 |
2018: 3 drugs
| Atorvastatin | 12 | $377 | $31 |
| Spironolactone | 14 | $134 | $10 |
| Carvedilol | 20 | $112 | $6 |
Money from drug and device companies
$3,341 in 2025
| 2025 | 3 | 6 | $2,520 | $3,341 |
| 2024 | 5 | 7 | $4,650 | $15,087 |
| 2023 | 6 | 21 | $16,036 | $18,129 |
| 2022 | 3 | 3 | $2,930 | $3,056 |
| 2021 | 2 | 2 | None | $50 |
| 2020 | 1 | 1 | None | $144 |
| 2019 | 6 | 15 | None | $1,138 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alnylam Pharmaceuticals | Amvuttra | $3,130 | 2 payments
|
| Abbott Laboratories | Cardiomems | $172 | 3 payments
|
| Endotronix | Cordella Pulomonary Artery Pressure Sensor | $39 | 1 payment
|
See all 6 published payments
| Endotronix | Meals · 2025-11-12 | Cordella Pulomonary Artery Pressure Sensor | $39 |
| Abbott Laboratories | Meals · 2025-11-10 | Cardiomems | $123 |
| Abbott Laboratories | Meals · 2025-11-10 | Cardiomems | $25 |
| Abbott Laboratories | Meals · 2025-11-10 | Cardiomems | $25 |
| Alnylam Pharmaceuticals | Paid to speak or teach · 2025-10-16 | Amvuttra | $2,520 |
| Alnylam Pharmaceuticals | Travel · 2025-09-13 | Amvuttra | $610 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $15,087
| Pfizer | None | $10,000 | 1 payment
|
| Novo Nordisk | None | $4,650 | 2 payments
|
| Amgen | Repatha | $165 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $146 | 2 payments
|
| Actelion Pharmaceuticals US | None | $125 | 1 payment
|
2023: $18,129
| Novo Nordisk | None | $15,773 | 3 payments
|
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $1,499 | 14 payments
|
| E.R. Squibb & Sons L.L.C. | None | $730 | 1 payment
|
| Alnylam Pharmaceuticals | Amvuttra | $82 | 1 payment
|
| Paragonix Technologies | Paragonix Sherpapak Cardiac Transport System | $41 | 1 payment
|
| Nuwellis | Aquadex Smartflow Console | $5 | 1 payment
|
2022: $3,056
| Pfizer | Vyndaqel | $2,200 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $730 | 1 payment
|
| Abbott Laboratories | Cardiomems | $126 | 1 payment
|
2021: $50
| Abbott Laboratories | Centrimag | $27 | 1 payment
|
| LivaNova USA | Lifesparc System | $22 | 1 payment
|
2020: $144
| Boston Scientific | Resonate | $144 | 1 payment
|
2019: $1,138
| Medtronic Vascular | Heartware Hvad | $494 | 6 payments
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $297 | 4 payments
|
| Actelion Pharmaceuticals US | Bosentan | $223 | 2 payments
|
| Alnylam Pharmaceuticals | None | $95 | 1 payment
|
| United Therapeutics | Orenitram | $22 | 1 payment
|
| Pfizer | Vyndaqel | $8 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ENDOTRONIX, INC. · Proactive-Hf · 2023 | Their institution | $226,151 |
| Alexion Pharmaceuticals, Inc. · A Phase 3,Radomized,Double-Blind,Placebo-Controlled,Multicenter Study To Evaluate the Efficacy and Safety of Amyloid Depleter Alxn2220 in Adult Participants Wiith Transthyretin Amyloid Cardiomyopathy Attr Cm · 2025 | Their institution | $175,872 |
| ENDOTRONIX, INC. · Proactive-Hf · 2024 | Their institution | $161,174 |
| ENDOTRONIX, INC. · Proactive-Hf · 2022 | Their institution | $110,893 |
| ENDOTRONIX, INC. · Proactive-Hf · 2025 | Their institution | $84,426 |
| ENDOTRONIX, INC. · Proactive-Hf · 2021 | Their institution | $79,440 |
| ENDOTRONIX, INC. · Proactive-Hf · 2020 | Their institution | $48,017 |
| Ionis Pharmaceuticals, Inc. · A Phase 3 Global Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy and Safety of Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025 | Their institution | $39,741 |
| Actelion Pharmaceuticals, Ltd · Opsumit · 2019 | Their institution | $32,524 |
| Eidos Therapeutics, Inc. · A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (Act-Early Trial) · 2025 | Their institution | $30,107 |
| Medtronic, Inc. · Psr-Mcs · 2021 | Their institution | $30,050 |
| Medtronic, Inc. · Psr-Mcs · 2020 | Their institution | $29,505 |
| Medtronic, Inc. · Psr-Mcs · 2019 | Their institution | $19,439 |
| PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2020 | Their institution | $17,357 |
| Medtronic, Inc. · Psr-Mcs · 2022 | Their institution | $15,003 |
| AstraZeneca UK Limited · A Non-Interventional, Prospective, Multi-Country Study Collecting Real-World Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Amyloid Transthyretin (Attr) Amyloidosis · 2025 | Their institution | $14,674 |
| Janssen Research & Development, LLC · Uptravi Selexipag the Users Drug Registry · 2021 | Their institution | $14,250 |
| Actelion Pharmaceuticals, Ltd · Clinical Study To Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation · 2020 | Their institution | $13,070 |
| AstraZeneca UK Limited · A Non-Interventional, Prospective, Multi-Country Study Collecting Real-World Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Amyloid Transthyretin (Attr) Amyloidosis · 2024 | Their institution | $12,977 |
| Ionis Pharmaceuticals, Inc. · An Openlabel Extension Study To Assess the Longterm Safety of Eplontersen Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025 | Their institution | $9,725 |
| Janssen Research & Development, LLC · Uptravi (Selexipag): the Users Drug Registry · 2020 | Their institution | $6,650 |
| Medtronic, Inc. · Psr-Mcs · 2025 | Their institution | $5,968 |
| PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2021 | Their institution | $4,239 |
| Janssen Research & Development, LLC · Uptravi Selexipag the Users Drug Registry · 2022 | Their institution | $3,680 |
| Medtronic, Inc. · Dt Pas · 2020 | Their institution | $2,455 |
| PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2019 | Their institution | $1,901 |
| Medtronic, Inc. · Psr-Mcs · 2024 | Their institution | $1,456 |
| Medtronic, Inc. · Psr-Mcs · 2023 | Their institution | $1,290 |
| AstraZeneca UK Limited · A Phase I/II Open-Label Study To Evaluate the Safety, Cellular Kinetics and Efficacy of Azd5851, A Chimeric Antigen Receptor T Cell (Car-T) Therapy Directed Against Gpc3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma · 2025 | Their institution | $1,120 |
| Medtronic, Inc. · Dt Pas · 2021 | Their institution | $858 |
| PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2022 | Their institution | $609 |
| Medtronic, Inc. · Apogee · 2020 | Their institution | $533 |
| Medtronic Vascular, Inc. · Psr-Mcs · 2019 | Their institution | $375 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720377146
- Licence
- CA A130155California A130155: Current · expires 2027-10-31
- Trained
- University of Pittsburgh School of Medicine, 2011 · 15 years ago
- Group
- University of California San Francisco · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- UCSF Division of Cardiology, 505 Parnassus Ave. Rm M1184, San Francisco, CA, 94143
- NPI first listed
- 2011-04-06
- NPI last updated
- 2021-09-16
- NPI record certified
- 2021-09-16
This is when the NPI record was last certified, not a medical board exam.